AMENDMENT NO. 9 TO CLINICAL TRIAL AGREEMENT BETWEENClinical Trial Agreement • March 8th, 2018 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 9 to Clinical Trial Agreement (the "Amendment" or "Amendment 9") is entered into as of November 22, 2017 (the "Effective Date"), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the "Group," "ECOG" or "ECOG-ACRIN"), and Syndax Pharmaceuticals, Inc. ("Company" or "Syndax").
ContractLicense Agreement • March 8th, 2018 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
